CN109874304B - Dpp-iv长效抑制剂的结晶及其盐 - Google Patents

Dpp-iv长效抑制剂的结晶及其盐 Download PDF

Info

Publication number
CN109874304B
CN109874304B CN201780044045.0A CN201780044045A CN109874304B CN 109874304 B CN109874304 B CN 109874304B CN 201780044045 A CN201780044045 A CN 201780044045A CN 109874304 B CN109874304 B CN 109874304B
Authority
CN
China
Prior art keywords
formula
compound
crystals
crystalline composition
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780044045.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109874304A (zh
Inventor
桑光明
刘林
张爱明
乔家彬
郭晓鹏
张喜全
夏春光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings (beijing) Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd, Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Publication of CN109874304A publication Critical patent/CN109874304A/zh
Application granted granted Critical
Publication of CN109874304B publication Critical patent/CN109874304B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780044045.0A 2016-08-12 2017-08-11 Dpp-iv长效抑制剂的结晶及其盐 Active CN109874304B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610666564 2016-08-12
CN201610665625 2016-08-12
CN2016106656259 2016-08-12
CN2016106665648 2016-08-12
PCT/CN2017/097046 WO2018028666A1 (zh) 2016-08-12 2017-08-11 Dpp-iv长效抑制剂的结晶及其盐

Publications (2)

Publication Number Publication Date
CN109874304A CN109874304A (zh) 2019-06-11
CN109874304B true CN109874304B (zh) 2021-06-25

Family

ID=61162770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780044045.0A Active CN109874304B (zh) 2016-08-12 2017-08-11 Dpp-iv长效抑制剂的结晶及其盐

Country Status (9)

Country Link
US (1) US10822319B2 (enExample)
EP (1) EP3498704A4 (enExample)
JP (1) JP6997760B2 (enExample)
KR (1) KR20190039754A (enExample)
CN (1) CN109874304B (enExample)
AU (1) AU2017308691B2 (enExample)
CA (1) CA3033890A1 (enExample)
RU (1) RU2753335C9 (enExample)
WO (1) WO2018028666A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108456196A (zh) * 2017-02-22 2018-08-28 四川科伦博泰生物医药股份有限公司 3-氨基四氢吡喃衍生物的盐及其多晶型、其制备方法和用途
CN111793071B (zh) * 2020-07-06 2021-06-04 四川凯科医药科技有限公司 奥格列汀的合成工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097931A2 (en) * 2006-02-15 2007-08-30 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2016127916A1 (zh) * 2015-02-12 2016-08-18 北京赛林泰医药技术有限公司 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
WO2017031918A1 (zh) * 2015-08-24 2017-03-02 四川科伦药物研究院有限公司 长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041016A2 (en) * 1999-12-02 2001-06-07 General Electric Company System and method for valuing loan portfolios using fuzzy clustering
JO2870B1 (en) * 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
TWI574965B (zh) * 2011-06-29 2017-03-21 默沙東藥廠 二肽基肽酶－ｉｖ抑制劑之新穎結晶型
US9937153B2 (en) * 2013-08-30 2018-04-10 Merck Sharp & Dohme Ltd. Oral pharmaceutical formulation of omarigliptin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097931A2 (en) * 2006-02-15 2007-08-30 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2016127916A1 (zh) * 2015-02-12 2016-08-18 北京赛林泰医药技术有限公司 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
WO2017031918A1 (zh) * 2015-08-24 2017-03-02 四川科伦药物研究院有限公司 长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法

Also Published As

Publication number Publication date
RU2019105352A3 (enExample) 2020-12-17
EP3498704A4 (en) 2020-03-04
RU2753335C9 (ru) 2021-09-20
CA3033890A1 (en) 2018-02-15
US10822319B2 (en) 2020-11-03
WO2018028666A1 (zh) 2018-02-15
AU2017308691A1 (en) 2019-03-28
US20190284153A1 (en) 2019-09-19
EP3498704A1 (en) 2019-06-19
JP6997760B2 (ja) 2022-01-18
RU2019105352A (ru) 2020-09-14
KR20190039754A (ko) 2019-04-15
AU2017308691B2 (en) 2021-12-16
JP2019527708A (ja) 2019-10-03
RU2753335C2 (ru) 2021-08-13
CN109874304A (zh) 2019-06-11

Similar Documents

Publication Publication Date Title
TWI576343B (zh) ５－氯－ｎ２－（２－異丙氧基－５－甲基－４－六氫吡啶－４－基－苯基）－ｎ４－［２－（丙烷－２－磺醯基）－苯基］－嘧啶－２，４－二胺之結晶型式
TWI496573B (zh) Ｎ－（第三丁氧羰基）－３－甲基－ｌ－纈胺醯基－（４ｒ）－４－（（７－氯－４－甲氧基－１－異喹啉）氧基）－ｎ－（（１ｒ，２ｓ）－１－（（環丙基磺醯基）胺甲醯基）－２－乙烯基環丙基）－ｌ－脯胺醯胺之結晶型
US8410288B2 (en) Polymorphs of Saxagliptin hydrochloride and processes for preparing them
CN107973783A (zh) 作为erk抑制剂的苯胺嘧啶衍生物
US20110014291A1 (en) Novel Polymorphs of Bosentan
US20110021547A1 (en) Substantially Pure and a Stable Crystalline Form of Bosentan
CN109874304B (zh) Dpp-iv长效抑制剂的结晶及其盐
US20140274914A1 (en) Ach-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
CN103626845B (zh) 作为糖原磷酸化酶抑制剂的芳基并吡咯-2-甲酰胺二肽衍生物、其制备方法及医药用途
HK40002160B (zh) Dpp-iv长效抑制剂的结晶及其盐
HRP980291A2 (en) Crystalline roxifiban
CN115141136A (zh) 特考韦瑞药的共晶及其制备方法
US8420668B2 (en) 1-(2H)-isoquinolone derivative
HK40002160A (en) Crystal of dpp-iv long-acting inhibitor and salt thereof
WO2021104186A1 (en) Novel salts of indoleamine 2,3-dioxygenase inhibitors
CN119306708A (zh) Flt3-hdac双靶点抑制剂及其制备方法和应用
CN119841853A (zh) 一种嘧啶甲酰胺类化合物的晶型及其制备方法
CN113214222A (zh) N-(芳基磺酰基)-吲哚-2-甲酰胺类FBPase抑制剂及其用途
HK1251879A1 (zh) 作为erk抑制剂的苯胺嘧啶衍生物
HK40083474A (en) Co-crystals, salts and solid forms of tenofovir alafenamide
HK40128266A (en) Co-crystals, salts and solid forms of tenofovir alafenamide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190605

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002160

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant before: Shouyao holding (Beijing) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant